$IMUC
EOM Pharmaceutical Holdings, Inc.

2015 Q3 Form 10-Q Financial Statement

#000156459015010219 Filed on November 09, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2014 Q4 2014 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.150M $920.0K $960.0K
YoY Change 19.79% -14.81% -15.79%
% of Gross Profit
Research & Development $2.662M $1.320M $1.490M
YoY Change 78.68% -7.69% 16.41%
% of Gross Profit
Depreciation & Amortization $6.997K $10.00K $12.93K
YoY Change -45.89% 0.0% -7.63%
% of Gross Profit
Operating Expenses $3.746M $2.240M $2.440M
YoY Change 53.52% -10.76% 0.83%
Operating Profit -$3.746M
YoY Change
Interest Expense $0.00 $110.0K $550.0K
YoY Change -100.0% -95.82% -139.86%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$3.401M -$2.130M -$1.890M
YoY Change 79.96% -1875.0% -50.13%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.401M -$2.127M -$1.889M
YoY Change 80.03% -1918.13% -50.2%
Net Earnings / Revenue
Basic Earnings Per Share -$0.03 -$0.03
Diluted Earnings Per Share -$1.504M -$0.03 -$0.03
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q3 2014 Q4 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $24.44M $23.22M $23.52M
YoY Change 3.91% -16.02% -20.08%
Cash & Equivalents $24.44M $23.22M $23.52M
Short-Term Investments
Other Short-Term Assets $1.330M $1.220M $1.000M
YoY Change 33.0% 59.82% 150.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $25.76M $24.44M $24.51M
YoY Change 5.12% -13.97% -17.86%
LONG-TERM ASSETS
Property, Plant & Equipment $200.0K $47.37K $60.00K
YoY Change 233.33% -28.71% -14.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.890M $583.5K $800.0K
YoY Change 511.25% 25.59% 2566.67%
Total Long-Term Assets $5.086M $736.4K $870.0K
YoY Change 484.59% 38.67% 770.0%
TOTAL ASSETS
Total Short-Term Assets $25.76M $24.44M $24.51M
Total Long-Term Assets $5.086M $736.4K $870.0K
Total Assets $30.85M $25.18M $25.38M
YoY Change 21.55% -13.0% -15.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $860.0K $322.0K $260.0K
YoY Change 230.77% -62.6% -52.73%
Accrued Expenses $1.150M $632.7K $980.0K
YoY Change 17.35% 243.88% 92.16%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.000M $1.289M $1.240M
YoY Change 61.29% -8.06% 15.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.560M $600.0K $710.0K
YoY Change 260.56% -43.4% -80.76%
Total Long-Term Liabilities $2.560M $600.0K $710.0K
YoY Change 260.56% -43.4% -80.76%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.000M $1.289M $1.240M
Total Long-Term Liabilities $2.560M $600.0K $710.0K
Total Liabilities $4.560M $1.887M $1.940M
YoY Change 135.05% -23.61% -59.24%
SHAREHOLDERS EQUITY
Retained Earnings -$61.35M
YoY Change 18.04%
Common Stock $84.64M
YoY Change 1470851.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $26.29M $23.29M $23.43M
YoY Change
Total Liabilities & Shareholders Equity $30.85M $25.18M $25.38M
YoY Change 21.55% -13.0% -15.23%

Cashflow Statement

Concept 2015 Q3 2014 Q4 2014 Q3
OPERATING ACTIVITIES
Net Income -$3.401M -$2.127M -$1.889M
YoY Change 80.03% -1918.13% -50.2%
Depreciation, Depletion And Amortization $6.997K $10.00K $12.93K
YoY Change -45.89% 0.0% -7.63%
Cash From Operating Activities -$6.310M -$2.110M -$2.510M
YoY Change 151.39% -22.99% 30.05%
INVESTING ACTIVITIES
Capital Expenditures -$160.0K $0.00 -$30.00K
YoY Change 433.33% 200.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities -$160.0K $0.00 -$30.00K
YoY Change 433.33% 200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.00K 1.810M 400.0K
YoY Change -97.5% 90.53% -93.24%
NET CHANGE
Cash From Operating Activities -6.310M -2.110M -2.510M
Cash From Investing Activities -160.0K 0.000 -30.00K
Cash From Financing Activities 10.00K 1.810M 400.0K
Net Change In Cash -6.460M -300.0K -2.140M
YoY Change 201.87% -83.24% -153.77%
FREE CASH FLOW
Cash From Operating Activities -$6.310M -$2.110M -$2.510M
Capital Expenditures -$160.0K $0.00 -$30.00K
Free Cash Flow -$6.150M -$2.110M -$2.480M
YoY Change 147.98% -22.99% 29.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q3 us-gaap Assets Current
AssetsCurrent
25764107
CY2015Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
4060977
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
84632209
us-gaap Operating Expenses
OperatingExpenses
7619933
imuc Equity Based Compensation
EquityBasedCompensation
666123
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7250360
us-gaap Net Income Loss
NetIncomeLoss
-7250360
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58933905
imuc Common Stock And Warrants Issued For Cash Net Of Offering Costs
CommonStockAndWarrantsIssuedForCashNetOfOfferingCosts
10296689
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
666123
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
9400
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6750
us-gaap Depreciation
Depreciation
20282
us-gaap Depreciation
Depreciation
36846
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
3
imuc Equity Based Compensation
EquityBasedCompensation
483455
us-gaap Restricted Stock Expense
RestrictedStockExpense
9400
us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
4060977
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
354142
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
535594
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
180139
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-13223771
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
169750
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
400
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-169750
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6750
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
202261
CY2015Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
175178
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
154896
CY2015Q3 us-gaap Depreciation
Depreciation
6997
CY2014Q3 us-gaap Depreciation
Depreciation
12930
imuc Nonrefundable And Noncreditable License And Maintenance Fee
NonrefundableAndNoncreditableLicenseAndMaintenanceFee
P12M
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
14599627
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
2681448
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
14606377
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
3726448
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1212856
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4130109
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27646351
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23516242
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:12pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Use of Estimates<font style="font-style:normal;"> &#8211; The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions about the future outcome of current transactions which may affect the reporting and disclosure of these transactions. Accordingly, actual results could differ from those estimates used in the preparation of these financial statements.</font></p></div>
CY2015Q3 imuc Working Capital
WorkingCapital
23759175
CY2014Q4 imuc Working Capital
WorkingCapital
23152970
CY2015Q3 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
23435936
CY2014Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
10427810
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.018
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0218
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y6M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y5M19D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.938
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.953
imuc Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeitures Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeituresRate
0.00
imuc Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeitures Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeituresRate
0.00
CY2015Q3 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
12020536
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2015Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2015Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38890839
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19495807
CY2015Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
372011
CY2015Q2 imuc License Agreement Termination Date
LicenseAgreementTerminationDate
2015-10-12
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
68432
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
94094
CY2015Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
14500000
us-gaap Loss Contingency Settlement Agreement Terms
LossContingencySettlementAgreementTerms
Services to be performed under the Agreement terminate on the earlier of (i) December 31, 2018, (ii) the date the parties mutually agree, (iii) at any time following the earlier of the one year anniversary of the date on which the Company notifies PCT that services in the semi-dedicated controlled environment room are to commence and August 1, 2016, on the last day of the month following at least 120 days’ written notice from the Company to PCT, or (iv) the last day of the month following at least 60 days’ written notice from the Company to PCT that the Company has received a clinical hold issued by the FDA ordering the Company to suspend clinical trials for ICT-107. Either party may terminate the Agreement in the event of the other party’s insolvency or for the other party’s material breach of its obligations under the Agreement if such breach remains uncured after 30 days of receiving written notice of such breach.
CY2015Q3 us-gaap Rental Properties
RentalProperties
8063
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
75000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
74000
imuc Percentage Of Annual Increase Of Monthly Base Rent
PercentageOfAnnualIncreaseOfMonthlyBaseRent
0.03
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
25662
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4111517
CY2015Q1 imuc Stock Issued During Period Shares Private Placement
StockIssuedDuringPeriodSharesPrivatePlacement
26650000
CY2015Q1 imuc Common Stock And Warrants Issued For Cash Per Share
CommonStockAndWarrantsIssuedForCashPerShare
0.60
CY2013Q2 imuc Rate Of Commission
RateOfCommission
0.030
CY2015Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0
imuc Percentage Of Fair Market Value Of Common Stock
PercentageOfFairMarketValueOfCommonStock
not be less than 100%
imuc Percentage Of Common Stock Voting Rights Held
PercentageOfCommonStockVotingRightsHeld
more than 10%
imuc Minimum Percentage Of Fair Market Value Of Common Stock
MinimumPercentageOfFairMarketValueOfCommonStock
less than 110%
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
12000000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
8000000
CY2005Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
6000000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
260000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9314765
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1818000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
50000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
379111
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10703654
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8080832
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.19
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.55
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.27
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.74
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.19
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.22
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y4M10D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P1Y10M24D
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2015Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2400000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P15M
CY2015Q1 us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
260000
CY2015Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.58
CY2010Q2 imuc Warrants Exercisable Period After Initial Issuance
WarrantsExercisablePeriodAfterInitialIssuance
P5Y
CY2011Q1 imuc Warrants Exercisable Period After Initial Issuance
WarrantsExercisablePeriodAfterInitialIssuance
P5Y
CY2012Q4 imuc Common Stock Of Public Offering
CommonStockOfPublicOffering
2823670
imuc Common Stock Of Public Offering
CommonStockOfPublicOffering
2854196
CY2014Q3 imuc Common Stock Of Public Offering
CommonStockOfPublicOffering
2869696
CY2012Q1 imuc Warrants Exercisable Period After Initial Issuance
WarrantsExercisablePeriodAfterInitialIssuance
P5Y
CY2012Q4 imuc Common Stock Shares Purchased Private Placement Warrant
CommonStockSharesPurchasedPrivatePlacementWarrant
2823670
CY2012Q1 imuc Charge To Financing Expense
ChargeToFinancingExpense
368524
CY2012Q4 imuc Charge To Financing Expense
ChargeToFinancingExpense
368524
CY2014Q4 imuc Common Stock Shares Purchased Private Placement Warrant
CommonStockSharesPurchasedPrivatePlacementWarrant
2949867
imuc Initial Valuation Of Warrants
InitialValuationOfWarrants
2476790
CY2014 imuc Charge To Financing Expense
ChargeToFinancingExpense
62683
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2014Q4 imuc Common Stock Of Public Offering
CommonStockOfPublicOffering
2949845
CY2015Q1 imuc Common Stock Of Public Offering
CommonStockOfPublicOffering
3666836
CY2012Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.87
CY2014Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.85
CY2014Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.84
CY2014Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.79
CY2015Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.44
CY2012Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.87
CY2015Q3 imuc Common Stock Shares Purchased Private Placement Warrant
CommonStockSharesPurchasedPrivatePlacementWarrant
3666836
CY2015Q1 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
4197375
CY2013Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1064810
imuc Issuance Of Warrants And Effect Of Repricing
IssuanceOfWarrantsAndEffectOfRepricing
4286314
imuc Issuance Of Warrants And Effect Of Repricing
IssuanceOfWarrantsAndEffectOfRepricing
34078
imuc Warrants Exercised
WarrantsExercised
0
imuc Warrants Exercised
WarrantsExercised
0
imuc Warrant Liability Gain Loss Included In Earnings
WarrantLiabilityGainLossIncludedInEarnings
2328298
imuc Warrant Liability Gain Loss Included In Earnings
WarrantLiabilityGainLossIncludedInEarnings
392940
imuc Warrants Liability Transfers Net
WarrantsLiabilityTransfersNet
0
imuc Warrants Liability Transfers Net
WarrantsLiabilityTransfersNet
0
CY2014Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
705948
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.34
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.34
us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.06
us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.06
imuc Change In Fair Value Of Warrant Liability For Income Taxes
ChangeInFairValueOfWarrantLiabilityForIncomeTaxes
0.12
imuc Change In Fair Value Of Warrant Liability For Income Taxes
ChangeInFairValueOfWarrantLiabilityForIncomeTaxes
-0.02
us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.28
us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.42
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2015Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
20155461
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
16302000
CY2015Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2503106
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2191000
CY2015Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
22658567
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
18493000
CY2015Q3 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2014Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
imuc Net Operating Losses Expire Date
NetOperatingLossesExpireDate
expire in 2022 and 2016

Files In Submission

Name View Source Status
0001564590-15-010219-index-headers.html Edgar Link pending
0001564590-15-010219-index.html Edgar Link pending
0001564590-15-010219.txt Edgar Link pending
0001564590-15-010219-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
imuc-10q_20150930.htm Edgar Link pending
imuc-20150930.xml Edgar Link completed
imuc-20150930.xsd Edgar Link pending
imuc-20150930_cal.xml Edgar Link unprocessable
imuc-20150930_def.xml Edgar Link unprocessable
imuc-20150930_lab.xml Edgar Link unprocessable
imuc-20150930_pre.xml Edgar Link unprocessable
imuc-ex101_15.htm Edgar Link pending
imuc-ex102_16.htm Edgar Link pending
imuc-ex311_12.htm Edgar Link pending
imuc-ex312_7.htm Edgar Link pending
imuc-ex321_9.htm Edgar Link pending
imuc-ex322_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending